Enovis (NYSE:ENOV) Given New $64.00 Price Target at Needham & Company LLC

Enovis (NYSE:ENOV) had its price objective reduced by Needham & Company LLC from $65.00 to $64.00 in a research note published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Enovis Stock Down 4.6 %

ENOV stock opened at $38.16 on Thursday. Enovis has a fifty-two week low of $38.08 and a fifty-two week high of $63.96. The company’s 50 day moving average price is $44.90 and its 200 day moving average price is $44.34. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -17.42 and a beta of 1.94.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. On average, equities research analysts anticipate that Enovis will post 2.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Enovis

Institutional investors have recently added to or reduced their stakes in the business. Raymond James & Associates raised its holdings in Enovis by 1,076.7% during the third quarter. Raymond James & Associates now owns 56,692 shares of the company’s stock worth $2,441,000 after purchasing an additional 51,874 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in Enovis by 9.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 15,500 shares of the company’s stock worth $667,000 after buying an additional 1,400 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in Enovis during the third quarter worth approximately $55,000. State of Alaska Department of Revenue lifted its stake in Enovis by 20.8% in the third quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company’s stock valued at $279,000 after buying an additional 1,115 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Enovis by 29.1% in the third quarter. US Bancorp DE now owns 17,962 shares of the company’s stock valued at $773,000 after acquiring an additional 4,050 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.